JPH01502195A - 細胞毒性結合物の増強法 - Google Patents

細胞毒性結合物の増強法

Info

Publication number
JPH01502195A
JPH01502195A JP63501891A JP50189188A JPH01502195A JP H01502195 A JPH01502195 A JP H01502195A JP 63501891 A JP63501891 A JP 63501891A JP 50189188 A JP50189188 A JP 50189188A JP H01502195 A JPH01502195 A JP H01502195A
Authority
JP
Japan
Prior art keywords
antigen
immunoglobulin
cells
tumor
antigens
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP63501891A
Other languages
English (en)
Japanese (ja)
Inventor
バイアース，ヴェラ・エス
ボールドウイン，ロバート・ダブリュー
スキャノン，パトリック・ジェイ
Original Assignee
ゾーマ・コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ゾーマ・コーポレーション filed Critical ゾーマ・コーポレーション
Publication of JPH01502195A publication Critical patent/JPH01502195A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6845—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a cytokine, e.g. growth factors, VEGF, TNF, a lymphokine or an interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
JP63501891A 1987-01-27 1988-01-26 細胞毒性結合物の増強法 Pending JPH01502195A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US704587A 1987-01-27 1987-01-27
US007,045 1987-01-27

Publications (1)

Publication Number Publication Date
JPH01502195A true JPH01502195A (ja) 1989-08-03

Family

ID=21723902

Family Applications (1)

Application Number Title Priority Date Filing Date
JP63501891A Pending JPH01502195A (ja) 1987-01-27 1988-01-26 細胞毒性結合物の増強法

Country Status (4)

Country Link
EP (1) EP0299057A4 (fr)
JP (1) JPH01502195A (fr)
KR (1) KR890700357A (fr)
WO (1) WO1988005309A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4921690A (en) * 1986-12-29 1990-05-01 City Of Hope Method of enhancing the biodistribution of antibody for localization in lesions
NZ225372A (en) * 1987-07-17 1991-04-26 Xoma Corp Immunotoxin composition comprising purified ricin-a-chain species
US5173293A (en) * 1989-02-23 1992-12-22 Becton Dickinson And Company Anti-T-cell antibodies as adjuvants
KR920702229A (ko) * 1990-06-29 1992-09-03 마에다 카쯔노스케 면역 독소 복합체
AU2593192A (en) 1992-09-14 1994-04-12 Oystein Fodstad Detection of specific target cells in specialized or mixed cell population and solutions containing mixed cell populations
NO180658C (no) 1994-03-10 1997-05-21 Oeystein Fodstad Fremgangsmåte og anordning for deteksjon av spesifikke målceller i spesialiserte eller blandede cellepopulasjoner og opplösninger som inneholder blandede cellepopulasjoner

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0811075B2 (ja) * 1982-06-30 1996-02-07 雄治 松岡 単クローン性抗ｃｅａ抗体
US4590071A (en) * 1984-09-25 1986-05-20 Xoma Corporation Human melanoma specific immunotoxins

Also Published As

Publication number Publication date
KR890700357A (ko) 1989-04-24
EP0299057A1 (fr) 1989-01-18
WO1988005309A1 (fr) 1988-07-28
EP0299057A4 (fr) 1990-02-22

Similar Documents

Publication Publication Date Title
US4925922A (en) Potentiation of cytotoxic conjugates
US4916213A (en) Ribosomal inhibiting protein-immunoglobulin conjugates with specificity for tumor cell surface antigens, and mixtures thereof
AU619232B2 (en) Novel antibodies
JPH10506881A (ja) 多剤耐性表現型を標的とするための多重特異性免疫複合体と抗体組成物
JP6577016B2 (ja) 治療及び診断のための抗コラーゲン抗体
JPH04502702A (ja) ヒト癌に対する新規なモノクローナル抗体
PT94565B (pt) Novos anticorpos reactivos com carcinomas humanos
US5034223A (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
JP3494592B2 (ja) 腫瘍治療剤
JPH10502544A (ja) 膜結合ｃｄ３０抗原の蛋白質分解性開裂及び遊離を防ぐ抗ｃｄ３０抗体
JPH04500510A (ja) 癌の診断、治療のための免疫結合体
USRE38008E1 (en) Methods for improved targeting of antibody, antibody fragments, hormones and other targeting agents, and conjugates thereof
JP2018518455A (ja) 治療用抗体およびその使用
EP0288520B1 (fr) Usage et composition permettant d'ameliorer le ciblage d'anticorps, de fragments d'anticorps, et de leur conjuges
WO1993002105A1 (fr) Composes trifonctionnels presentant une specificite contre les cellules resistant a plusieurs medicaments____________________
US5407805A (en) Monoclonal antibody reactive to various human leukemia and lymphoma cells and methods of using same for diagnosis and treatment
JPH01502195A (ja) 細胞毒性結合物の増強法
US20190389960A1 (en) Compositions and methods for c1q targeted therapy
AU8071187A (en) Monoclonal paratopic molecule directed to human ganglioside gd2
US6440733B1 (en) Monoclonal antibodies recognizing antigens on the surface of endothelial cells of tumor vessel
Oldham et al. Individually specified drug immunoconjugates in cancer treatment
EP0256471A2 (fr) Conjugués cytotoxiques pour la thérapie du cancer
US5523085A (en) Monoclonal antibody in destruction of small cell lung carcinoma
JP2919961B2 (ja) 扁平上皮癌の抗原分化のためのモノクローナル抗体および同抗体の使用法
US5169775A (en) Monoclonal antibodies against lymphoma-associated antigens, hybrid cell lines producing these antibodies